Combination Therapy with Tirzepatide and Menopause Hormone Therapy Enhances Weight Loss in Postmenopausal Women
A groundbreaking study reveals that combining tirzepatide with menopause hormone therapy significantly boosts weight loss in postmenopausal women, offering new hope for obesity management.
Recent research presented at ENDO 2025, the American Endocrine Society's annual meeting held in San Francisco, highlights a significant advancement in managing weight among postmenopausal women. The study indicates that combining the obesity medication tirzepatide with menopause hormone therapy (MHT) results in greater weight loss compared to using tirzepatide alone. The findings suggest that this combined approach could be more effective in addressing the hormonal and metabolic changes that typically lead to weight gain after menopause.
The study involved analyzing the electronic medical records of 120 postmenopausal women over an 18-month period. Among them, 40 women received both tirzepatide and MHT, while 80 women were treated with tirzepatide only. The results demonstrated that women on the combined therapy experienced an average total body weight loss of 17%, which was higher than the 14% observed in the tirzepatide-only group. Additionally, 45% of women using MHT alongside tirzepatide achieved at least a 20% reduction in total body weight—significantly more than the 18% in the non-MHT group.
Experts believe that hormonal changes during menopause contribute to increased abdominal fat, reduced muscle mass, and altered energy expenditure—factors that promote weight gain and elevate risks for heart disease and other health conditions. The combination therapy appears to counteract these changes more effectively, leading to improved weight management and associated health benefits.
Dr. Regina Castaneda from the Mayo Clinic emphasized the importance of these findings, noting that they represent the first evidence of increased treatment efficacy when pairing tirzepatide with MHT. "This opens new avenues for personalized intervention strategies to combat obesity in postmenopausal women," she said.
Further research is essential to understand the mechanisms behind this synergy and to develop accessible, tailored treatment plans for women experiencing menopause-related weight challenges. The study underscores the potential for combination therapies to enhance health outcomes and reduce the burden of obesity-related diseases among postmenopausal populations.
Source: https://medicalxpress.com/news/2025-07-combination-obesity-medication-tirzepatide-menopause.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
UK Investigates Genetic Factors Linking Obesity Medications and Pancreatitis Risk
The UK is investigating genetic factors that may increase the risk of pancreatitis in patients using obesity drugs like Wegovy and Zepbound. Authorities are calling for reports from affected individuals to better understand this potential genetic link and ensure patient safety.
Dairy Cattle H5N1 Virus Stays Bird-Adapted with Minimal Human Transmission
Recent study indicates that the H5N1 virus found in dairy cattle remains bird-adapted with minimal risk of human transmission, emphasizing ongoing vigilance and effective treatments.
Innovative 3D Bioprinted Brain Model Advances Understanding of Neurological Disorders
Researchers have developed a 3D bioprinted brain model that closely mimics human neural architecture, offering new insights into neurodegenerative diseases and alcohol-induced neurotoxicity.
